
A New Era in TED: Navigating Choice, Sequencing, and Long-Term Care
The management of thyroid eye disease (TED) is entering a new era marked by the availability of multiple FDA-approved IGF-1R-targeted therapies and a growing pipeline of emerging treatment options. As the treatment landscape continues to evolve, clinicians require practical guidance to make informed, patient-centered therapeutic decisions across the disease continuum. Delivered in a dynamic Rapid-Fire Roundtable format, this activity will provide participants with expert insights into available therapies, highlighting key differences in clinical evidence, safety profiles, patient selection, retreatment strategies, and challenges to real-world implementation. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box:


















